Emanuelle M. Rizk

497 total citations
17 papers, 217 citations indexed

About

Emanuelle M. Rizk is a scholar working on Oncology, Immunology and Epidemiology. According to data from OpenAlex, Emanuelle M. Rizk has authored 17 papers receiving a total of 217 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Immunology and 4 papers in Epidemiology. Recurrent topics in Emanuelle M. Rizk's work include Cancer Immunotherapy and Biomarkers (8 papers), Immunotherapy and Immune Responses (7 papers) and CAR-T cell therapy research (5 papers). Emanuelle M. Rizk is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Immunotherapy and Immune Responses (7 papers) and CAR-T cell therapy research (5 papers). Emanuelle M. Rizk collaborates with scholars based in United States, Canada and United Kingdom. Emanuelle M. Rizk's co-authors include Yvonne M. Saenger, Robyn D. Gartrell, Luke W. Barker, Balázs Ács, David L. Rimm, Fahad Shabbir Ahmed, Larisa J. Geskin, Swati Gupta, Bonnie Gould Rothberg and Pok Fai Wong and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Emanuelle M. Rizk

16 papers receiving 216 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Emanuelle M. Rizk United States 7 144 69 68 28 25 17 217
Tze Heng Tan Germany 4 134 0.9× 75 1.1× 72 1.1× 33 1.2× 6 0.2× 6 265
Bridget Hilton United Kingdom 6 105 0.7× 46 0.7× 71 1.0× 23 0.8× 15 0.6× 10 248
Angela Sandru Romania 8 159 1.1× 155 2.2× 53 0.8× 18 0.6× 13 0.5× 11 299
JungHo Kong South Korea 7 99 0.7× 99 1.4× 36 0.5× 31 1.1× 9 0.4× 13 229
Jelmar Quist United Kingdom 10 102 0.7× 127 1.8× 29 0.4× 14 0.5× 29 1.2× 22 259
Banri Tsuda Japan 10 191 1.3× 77 1.1× 139 2.0× 53 1.9× 13 0.5× 27 333
Guangdong Qiao China 9 97 0.7× 105 1.5× 95 1.4× 20 0.7× 9 0.4× 31 264
Kota Itahashi Japan 8 173 1.2× 109 1.6× 155 2.3× 16 0.6× 11 0.4× 16 328
Michael Leisch Austria 9 72 0.5× 115 1.7× 55 0.8× 14 0.5× 15 0.6× 14 273
Kamran Kafi United States 11 130 0.9× 96 1.4× 104 1.5× 109 3.9× 32 1.3× 17 342

Countries citing papers authored by Emanuelle M. Rizk

Since Specialization
Citations

This map shows the geographic impact of Emanuelle M. Rizk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emanuelle M. Rizk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emanuelle M. Rizk more than expected).

Fields of papers citing papers by Emanuelle M. Rizk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emanuelle M. Rizk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emanuelle M. Rizk. The network helps show where Emanuelle M. Rizk may publish in the future.

Co-authorship network of co-authors of Emanuelle M. Rizk

This figure shows the co-authorship network connecting the top 25 collaborators of Emanuelle M. Rizk. A scholar is included among the top collaborators of Emanuelle M. Rizk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emanuelle M. Rizk. Emanuelle M. Rizk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Rizk, Emanuelle M., Mohamed Sherief, Michael Chang, et al.. (2024). Molecular characterization of gliosarcoma reveals prognostic biomarkers and clinical parallels with glioblastoma. Journal of Neuro-Oncology. 171(2). 403–411.
2.
Thompson, Katherine G., Raghav Tripathi, Emanuelle M. Rizk, et al.. (2023). Predictors of patient satisfaction with Mohs micrographic surgery at time of surgery and 3 months postsurgery: A prospective cohort study. Journal of the American Academy of Dermatology. 89(5). 992–1000. 4 indexed citations
3.
Rizk, Emanuelle M., et al.. (2023). Rates of Internal Hiring of Ophthalmology Faculty from their Institution of Training at Top Academic Medical Centers: A Cross-Sectional Study. SHILAP Revista de lepidopterología. 15(2). e154–e161. 2 indexed citations
4.
Gartrell, Robyn D., Zoë Blake, Emanuelle M. Rizk, et al.. (2022). Combination immunotherapy including OncoVEXmGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma. Cancer Immunology Immunotherapy. 71(8). 1837–1849. 4 indexed citations
5.
Trager, Megan H., Emanuelle M. Rizk, Sharon Rose, et al.. (2021). Transcriptomic analysis identifies differences in gene expression in actinic keratoses after treatment with imiquimod and between responders and non responders. Scientific Reports. 11(1). 8775–8775. 2 indexed citations
6.
Gartrell, Robyn D., Andrew Chen, Emanuelle M. Rizk, et al.. (2020). Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma. Cancer Research. 80(5). 1078–1087. 17 indexed citations
7.
Yeh, Randy, Megan H. Trager, Emanuelle M. Rizk, et al.. (2020). FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With Pembrolizumab. Clinical Nuclear Medicine. 45(4). 267–275. 11 indexed citations
8.
Trager, Megan H., Robyn D. Gartrell, Emanuelle M. Rizk, et al.. (2020). Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec. Melanoma Research. 30(4). 410–415. 5 indexed citations
9.
Moore, Michael, Emanuelle M. Rizk, Megan H. Trager, et al.. (2020). Effect of automated TIL quantification in early-stage melanoma on accuracy of standard T staging using AJCC guidelines.. Journal of Clinical Oncology. 38(15_suppl). 10076–10076. 2 indexed citations
10.
Rizk, Emanuelle M., et al.. (2019). Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy. Hematology/Oncology Clinics of North America. 33(2). 291–299. 26 indexed citations
11.
Ács, Balázs, Fahad Shabbir Ahmed, Swati Gupta, et al.. (2019). An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma. Nature Communications. 10(1). 5440–5440. 64 indexed citations
12.
Rizk, Emanuelle M., Megan H. Trager, Michael Moore, et al.. (2019). Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma. American Journal of Clinical Dermatology. 21(1). 1–11. 17 indexed citations
13.
Gartrell, Robyn D., Douglas K. Marks, Emanuelle M. Rizk, et al.. (2019). Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma. Clinical Cancer Research. 25(8). 2494–2502. 17 indexed citations
14.
Robinson, Eric, Robyn D. Gartrell, Yang Chen, et al.. (2019). Prediction of distant melanoma recurrence from primary tumor digital H&E images using deep learning.. Journal of Clinical Oncology. 37(15_suppl). 9577–9577. 3 indexed citations
15.
Rizk, Emanuelle M., Robyn D. Gartrell, Jay Oza, et al.. (2019). Nivolumab for hepatocellular carcinoma (HCC) in a real-world context.. Journal of Clinical Oncology. 37(15_suppl). e15675–e15675. 5 indexed citations
16.
Lopez, Adriana T., Robyn D. Gartrell, Kimberly M. Komatsubara, et al.. (2018). The Role of Oncolytic Viruses in the Treatment of Melanoma. Current Oncology Reports. 20(10). 80–80. 37 indexed citations
17.
Gartrell, Robyn D., Zoë Blake, Rolando Pérez‐Lorenzo, et al.. (2018). Effect of combination immunotherapy on tumor growth, survival, and intratumoral immune infiltration in transgenic murine model of melanoma.. Journal of Clinical Oncology. 36(15_suppl). e21610–e21610. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tze Heng Tan Breakdown of academic impact, for papers by Bridget Hilton Breakdown of academic impact, for papers by Angela Sandru Breakdown of academic impact, for papers by JungHo Kong Breakdown of academic impact, for papers by Jelmar Quist Breakdown of academic impact, for papers by Banri Tsuda Breakdown of academic impact, for papers by Guangdong Qiao Breakdown of academic impact, for papers by Kota Itahashi Breakdown of academic impact, for papers by Michael Leisch Breakdown of academic impact, for papers by Kamran Kafi
Rankless by CCL
2026